Becton Dickinson Resumes U.S. Shipments of ChloraPrep

Dow Jones

05/29

By Dean Seal

Becton Dickinson has resumed shipments of its antiseptic skin preparation agent ChloraPrep in the U.S. after placing a voluntary hold on it earlier this month.

The medical-technology company said it has done additional final release testing on ChloraPrep that has been acceptable, and there have been no patient safety signals.

Shipments had been placed on hold after Becton Dickinson received a warning letter from the Federal Drug Administration tied to an October inspection of the company's El Paso manufacturing facility.

The letter cited deficiencies in the company's compliance with manufacturing standards, including inadequate investigation of complaints, insufficient laboratory controls and shortcomings in equipment clearing, among others, according to a regulatory filing.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

May 29, 2026 09:21 ET (13:21 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2639620010"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2639620010\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2639620010?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 21:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2639620010","market":"sh","top_or_hot":-1,"title":"Becton Dickinson Resumes U.S. Shipments of ChloraPrep","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Becton Dickinson has resumed shipments of its antiseptic skin preparation agent ChloraPrep in the U.S. after placing a voluntary hold on it earlier this month. \n</p>\n<p>\n  The medical-technology company said it has done additional final release testing on ChloraPrep that has been acceptable, and there have been no patient safety signals. \n</p>\n<p>\n  Shipments had been placed on hold after Becton Dickinson received a warning letter from the Federal Drug Administration tied to an October inspection of the company's El Paso manufacturing facility. \n</p>\n<p>\n  The letter cited deficiencies in the company's compliance with manufacturing standards, including inadequate investigation of complaints, insufficient laboratory controls and shortcomings in equipment clearing, among others, according to a regulatory filing. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 29, 2026 09:21 ET (13:21 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Becton Dickinson Resumes U.S. Shipments of ChloraPrep</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBecton Dickinson Resumes U.S. Shipments of ChloraPrep\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-05-29 21:21</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Becton Dickinson has resumed shipments of its antiseptic skin preparation agent ChloraPrep in the U.S. after placing a voluntary hold on it earlier this month. \n</p>\n<p>\n  The medical-technology company said it has done additional final release testing on ChloraPrep that has been acceptable, and there have been no patient safety signals. \n</p>\n<p>\n  Shipments had been placed on hold after Becton Dickinson received a warning letter from the Federal Drug Administration tied to an October inspection of the company's El Paso manufacturing facility. \n</p>\n<p>\n  The letter cited deficiencies in the company's compliance with manufacturing standards, including inadequate investigation of complaints, insufficient laboratory controls and shortcomings in equipment clearing, among others, according to a regulatory filing. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 29, 2026 09:21 ET (13:21 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BFXG1179.USD","symbol_name":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2639620010","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2639620010","pubTimestamp":1780060860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Becton Dickinson has resumed shipments of its antiseptic skin preparation agent ChloraPrep in the U.S. after placing a voluntary hold on it earlier this month.The medical-technology company said it has done additional final release testing on ChloraPrep that has been acceptable, and there have been no patient safety signals.Shipments had been placed on hold after Becton Dickinson received a warning letter from the Federal Drug Administration tied to an October inspection of the company's El Paso manufacturing facility.The letter cited deficiencies in the company's compliance with manufacturing standards, including inadequate investigation of complaints, insufficient laboratory controls and shortcomings in equipment clearing, among others, according to a regulatory filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","LU0068578508.USD":"First Eagle Amundi International Cl AU-C USD","BK4082":"医疗保健设备","BK4504":"桥水持仓","LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","LU1150488218.USD":"First Eagle Amundi Income Builder AU2-MD USD","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","BK4588":"碎股","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","LU0130518102.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"R\" INC","LU1150488135.SGD":"First Eagle Amundi Income Builder AHS-MD SGD-H","LU0477156797.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","LU0985489474.SGD":"First Eagle Amundi International AHS-C SGD-H","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0878866978.SGD":"First Eagle Amundi International AHS-QD SGD-H","LU1489326972.SGD":"First Eagle Amundi International AHS-MD SGD-H","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","BK4585":"ETF&股票定投概念","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BDX":"碧迪医疗","LU0433182093.SGD":"First Eagle Amundi International AS-C SGD","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC"},"translate_title":"Becton Dickinson恢复ChloraPrep在美国的发货","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BDX":1.5},"content_text":"By Dean Seal \n\n\n \n\n\n  Becton Dickinson has resumed shipments of its antiseptic skin preparation agent ChloraPrep in the U.S. after placing a voluntary hold on it earlier this month. \n\n\n  The medical-technology company said it has done additional final release testing on ChloraPrep that has been acceptable, and there have been no patient safety signals. \n\n\n  Shipments had been placed on hold after Becton Dickinson received a warning letter from the Federal Drug Administration tied to an October inspection of the company's El Paso manufacturing facility. \n\n\n  The letter cited deficiencies in the company's compliance with manufacturing standards, including inadequate investigation of complaints, insufficient laboratory controls and shortcomings in equipment clearing, among others, according to a regulatory filing. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 29, 2026 09:21 ET (13:21 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}